ICMJE DISCLOSURE FORM

Date:	Angust	2021					
Your Name:		CLAIRE	M	RICK	ARD		
Manuscript Title:		Lett	er -	from	Aust	ralia	
Manuscript number (if known):_		M21-3	295	1			
		-					

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	X None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X None	
3	Royalties or licenses	_X None	

4	Consulting fees	_X None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_X None
6	Payment for expert testimony	X None
7	Support for attending meetings and/or travel	_X None
8	Patents planned, issued or pending	_X None
9	Participation on a Data Safety Monitoring Board or Advisory Board	_X None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_X None
11	Stock or stock options	_X None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_X None
13	Other financial or non- financial interests	_X None

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date:	10/6/2021
Your Name:	David Paterson
Manuscript Title:	Letter from Australia - a never ending pandemic?
Manuscript Number (if known):	M21-3295

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning c	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	□ None Shionogi MSD Pfizer	Payment to institution Payment to institution Payment to institution
3	Royalties or licenses	☑ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees		
		Spero Therapeutics	To me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	None MSD Pfizer Shionogi	To me To me To me
	educational events		
6	Payment for expert testimony	☑ None	
7	Support for attending meetings and/or travel	None Shionogi	To me
8	Patents planned, issued or pending	☑ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None MSD, QPex, Janssen, Spero, Accelerate Diagnostics, Lysovant, Symvivo	To me
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None Board member of Australasian Society for Infectious Diseases	Unpaid

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Please place an "X" next to the following statement to indicate your agreement:				